Related Experiment Videos
Synkavit and its direct labelling with iodine-125, as a potential anti-cancer drug
Abstract:
The compound known as "synkavit" is a diphosphate derivative of vitamin K3 (menadion), which is capable of being selectively accumulated in certain tumour cells, and covalently bonded to DNA producing considerable DNA damage. On the other hand, iodine-125 nuclide incorporated into the nucleus of living cells causes extreme radiotoxic effects. Consequently, synkavit can be used as a specific carrier of iodine-125 into the nucleus of tumour cells. Thus, its iodo-derivatives have become interesting agents on the potential application of iodine-125 in cancer therapy. 6-Iodo-synkavit is a unique iodo-derivative described in the literature. In addition, its synthesis and radioiodination is still problematic, and consequently the results obtained using 6-iodo-synkavit labelled with iodine-125 remains in question. For this reason, the synthesis of 6-iodo-synkavit was examined in this study. It is finally determined that a mixture of different iodo-isomers of synkavit has been produced rather than its specific 6-iodo-isomer, when the synthetic sequence was begun with the direct sulfonation of 2-methyl-naphthalene. On the other hand, it is also determined that synkavit can directly be radioiodinated using different iodination techniques, and iodogen especially can be successfully used as an oxidative agent.
Insights
Synkavit, a vitamin K3 derivative, can deliver radioactive iodine-125 to tumor cells for cancer therapy. Direct radioiodination of synkavit is feasible, overcoming issues with specific iodo-synkavit synthesis.
Area of Science:
- Biochemistry
- Radiochemistry
- Oncology
Background:
- Synkavit (vitamin K3 diphosphate derivative) selectively accumulates in tumor cells, causing DNA damage.
- Iodine-125 (¹²⁵I) causes extreme radiotoxicity when localized in cell nuclei.
- Iodo-synkavit derivatives are explored for targeted cancer therapy using ¹²⁵I.
Purpose of the Study:
- To investigate the synthesis of 6-iodo-synkavit for potential cancer therapy.
- To evaluate direct radioiodination methods for synkavit.
Main Methods:
- Synthesis of 6-iodo-synkavit starting with sulfonation of 2-methyl-naphthalene.
- Direct radioiodination of synkavit using various iodination techniques.
Main Results:
- Direct sulfonation of 2-methyl-naphthalene yielded a mixture of iodo-synkavit isomers, not the specific 6-iodo-synkavit.
- Synkavit can be directly radioiodinated effectively, with iodogen proving a successful oxidative agent.
Conclusions:
- The synthesis of specific 6-iodo-synkavit via direct sulfonation is problematic.
- Direct radioiodination of synkavit is a viable method for preparing ¹²⁵I-labeled agents for cancer therapy.